NASDAQ: IMGN
$ 7.89 +0.29 (3.82%)
Day High: 7.89
Day Low:  7.51
Volume:    971,100
4:00 PM ET on
Mar 2, 2015

Delayed ~20 min., by eSignal.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever ImmunoGen, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Corporate Profile

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's antibody-drug conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product approved with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing, with nine additional compounds in the clinic through the Company's partnerships with Amgen, Bayer HealthCare, Biotest, Novartis and Sanofi. More information about ImmunoGen can be found at  www.immunogen.com.

Shareholder Inquiries

Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.

Corporate Headquarters

ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477
Phone: (781) 895-0600
Email: info@immunogen.com

 

Corporate Counsel

Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
Boston, MA

Transfer Agent and Registrar

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
Phone: (877) 830-4936
Fax: (215) 553-5402
E-mail: shareholder@broadridge.com

 

Independent Accountants

Ernst & Young LLP
Boston, MA


You are now leaving this website. If you would like to continue, click Continue.
CancelContinue